Upcoming event
18th European Multidisciplinary Congress on Urological Cancers
Back

Tag: ADT

Darolutamide with androgen deprivation therapy and definitive or salvage locoregional radiation therapyfor localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)

Perioperative apalutamide plus androgen-deprivation therapy with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients with high-risk localized or locally advanced prostate cancer: PROTEUS substudy

Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: A secondary analysis of the PROTECT randomised clinical trial

An update on fluorescence guided surgery

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Effect on survival of ADT alone compared to ADT combined with concurrent RT to the prostate in patients with primary bone metastatic PCa in a prospective randomised clinical trial: data from the HORRAD trial

Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)

Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less